FrancophonIA/ELRC3.0 huggingface dataset:
English: Pigs: Meat and offal: 5 days Horses: Meat and offal:
Estonian: Veistel: lihale ja söödavatele kudedele: 15 päeva; piimale: 5 päeva.
English: Meloxicam 5 mg/ml
Estonian: Meloksikaami 5 mg/ml
English: Loxicom 1.5 mg/ml oral suspension for dogs
Estonian: Loxicom 1,5 mg/ml suukaudne suspensioon koertele
English: Equidae
Estonian: Sobimatus
English: Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight (i.e. 0.667 ml/10 kg bodyweight).
Estonian: Ravi jätkatakse üks kord päevas suukaudse manustamisega (24 tunniste intervallidega) säilitusannusega 0,1 mg meloksikaami/kg kehamassi kohta (s.o 0.667 ml/10 kg kehamassi kohta).
English: Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects.
Estonian: Meloksikaam on oksikaamide klassi kuuluv mittesteroidne põletikuvastane ravim, mille toime seisneb prostaglandiinide sünteesi inhibeerimises, millega avaldatakse põletikuvastast, valuvaigistavat, antieksudatiivset ja palavikuvastast toimet.
English: Excipients: Ethanol, anhydrous
Estonian: Abiained: Etanool, veevaba
English: Loxicom 0.5 mg/ml oral suspension for dogs
Estonian: Loxicom 0,5 mg/ml suukaudne suspensioon koertele
English: Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Estonian: Ravi jätkatakse üks kord päevas suukaudse manustamisega (24-tunniste intervallidega) säilitusannusega 0,1 mg meloksikaami/kg kehamassi kohta.
English: Loxicom 1.5 mg/ml oral suspension for dogs meloxicam
Estonian: Loxicom 1,5 mg/ml suukaudne suspensioon koertele meloksikaam
English: Cattle, pigs and horses.
Estonian: Veis, siga ja hobune.
English: Carton Box labelling
Estonian: Pappkarbi märgistus
English: Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in cats.
Estonian: Valu ja põletiku leevendamine kassidel ägedate ja krooniliste lihas-skeleti kahjustuste korral.
English: EU/2/08/090/003 EU/2/08/090/004 EU/2/08/090/005 EU/2/08/090/032 EU/2/08/090/033
Estonian: EU/2/08/090/005 EU/2/08/090/032 EU/2/08/090/033
English: MANUFACTURER'S BATCH NUMBER BN
Estonian: <PARTII> <Lot> <BN>{number}
English: EXP {month/year} Shelf life after first opening the immediate packaging: 28 days
Estonian: EXP {kuu/aasta} Kõlblikkusaeg pärast vahetu pakendi esmast avamist: 28 päeva.
English: Ethanol, anhydrous
Estonian: Etanool, veevaba
English: In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.
Estonian: Väga harvadel juhtudel on täheldatud verist kõhulahtisust, veriokset, seedetrakti haavandeid ja maksaensüümide taseme tõusu.
English: Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight (i.e. 2 ml/10 kg bodyweight).
Estonian: Ravi jätkatakse üks kord päevas suukaudse manustamisega (24- tunniste intervallidega) säilitusannusega 0,1 mg meloksikaami/kg kehamassi kohta (s.o 2 ml/10 kg kehamassi kohta.
English: In case of overdose, symptomatic treatment should be initiated.
Estonian: Üleannustamise korral tuleb alustada sümptomaatilist ravi.
English: Loxicom 20 mg/ml solution for Injection for cattle, pigs and horses meloxicam2.
Estonian: Loxicom 20 mg/ml süstelahus veistele, sigadele ja hobustele meloksikaam
English: Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.
Estonian: Põletiku ja valu leevendamine hobustel ägedate ja krooniliste lihas-skeleti kahjustuste korral.
English: Ethanol, anhydrous 150 mg
Estonian: meloksikaam 50 mg
English: Loxicom 5 mg/ml solution for injection for dogs and cats meloxicam2.
Estonian: Loxicom 5 mg/ml süstelahus koertele ja kassidele meloksikaam
English: Shelf-life after first opening the immediate packaging: 28 days
Estonian: Kõlblikkusaeg pärast vahetu pakendi esmast avamist: 28 päeva
English: Excipient:
Estonian: DKoerad:
English: Oral paste
Estonian: Pappkarp
English: METHOD AND ROUTE OF ADMINISTRATION
Estonian: Annustamine ja manustamisviis
English: Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg bodyweight.
Estonian: Ravi tuleks jätkata suukaudse manustamisega üks kord päevas (24-tunniste vahedega) säilitava annusena 0,05 mg meloksikaami/kg kehamassi kohta.
English: Loxicom 0.5 mg/ml oral suspension for dogs meloxicam
Estonian: Loxicom 0,5 mg/ml suukaudne suspensioon koertele meloksikaam
English: WITHDRAWAL PERIOD(S)
Estonian: Jääkide piirnormi d
English: Loxicom 0.5 mg/ml oral suspension for cats meloxicam2.
Estonian: Loxicom 0,5 mg/ml suukaudne suspensioon kassidele Meloksikaam
English: 15 and 30 ml bottle
Estonian: 15 ml ja 30 ml pudel
English: Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Estonian: Eelnev ravi teiste põletikuvastaste ainetega võib põhjustada täiendavaid või raskemaid kõrvaltoimeid, mistõttu tuleb enne ravi alustamist jätta vähemalt 24-tunnine ravivaba periood nende veterinaarravimitega.
English: Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight (i.e. 4 ml/10 kg bodyweight) on the first day.
Estonian: Algannus esimesel päeval on ühekordne doos 0,2 mg meloksikaami/kg kehamassi kohta (s.o 4 ml/10 kg kehamassi kohta).
English: In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports) loss of appetite, lethargy, abdominal pain and colitis have been reported.
Estonian: Väga harvadel juhtudel (vähem kui 1-l loomal 10,000-st ravitud loomast, kaasaarvatud üksikjuhud) on esinenud isutust, letargiat, kõhuvalu ja koliiti.
English: Do not use after the expiry date (EXP) stated on the carton and vial after EXP.
Estonian: Ärge kasutage pärast kõlblikkusaega, mis on märgitud karbil ja viaalil pärast EXP.
English: Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day.
Estonian: Algseks raviks on esimesel päeval ühekordne suukaudne annus 0,2 mg meloksikaami/kg kehamassi kohta.
English: More than 97 % of meloxicam is bound to plasma proteins.
Estonian: Umbes 97% meloksikaamist seondub plasmavalkudega.
English: Shelf-life after first opening the container: 28 days.
Estonian: Kõlblikkusaeg pärast klaasviaali esmast avamist: 28 päeva.
English: Initial treatment is a single oral dose of 0.1 mg meloxicam/kg bodyweight on the first day.
Estonian: Algseks raviks esimesel päeval on ühekordne suukaudne annus 0,1 mg meloksikaami/kg kehamassi kohta.
English: In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports) gastrointestinal ulceration and elevated liver enzymes have been reported.
Estonian: Väga harvadel juhtudel (vähem kui 1-l loomal 10,000-st ravitud loomast, kaasaarvatud üksikjuhud) on täheldatud seedetrakti haavandeid ja maksaensüümide taseme tõusu.
English: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Estonian: Põletiku ja valu leevendamiseks nii ägedate kui krooniliste lihas-skeleti kahjustuste korral koertel.
English: Meloxicam 20 mg/ml Ethanol 150 mg/ml
Estonian: Meloksikaam 20 mg/ml Etanooli, veevaba
English: Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.
Estonian: Vältida kasutamist dehüdreerunud, hüpovoleemilistel ja hüpotensiooniga loomadel, kuna on potentsiaalne risk neeru toksilisusele.
English: Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Estonian: Mitte kasutada loomadel, kellel on seedetrakti häired, nagu ärritus ja hemorraagia, kahjustunud maksa-, südame- või neerufunktsioon ja hemorraagilised häired.
English: In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports), haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.
Estonian: Väga harvadel juhtudel (vähem kui 1-l loomal 10,000-st ravitud loomast, kaasaarvatud üksikjuhud) täheldati verist kõhulahtisust, veriokset, seedetrakti haavandeid ja maksaensüümide taseme tõusu.
English: In very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported.
Estonian: Väga harvadel juhtudel on täheldatud verist kõhulahtisust, veriokset ja seedetrakti haavandeid.
English: Dogs: Single administration of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg).
Estonian: Ühekordne süstimine doosis 0,2 mg meloksikaami/kg kehamassi kohta (s.o 0.4 ml/10 kg kehamassi kohta).
English: Typical adverse drug reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Estonian: Tüüpilised kõrvaltoimed, mida mittesteroidsete põletikuvastaste ravimite (NSAIDe) kasutamisel aegajalt täheldatakse on isu kadu, oksendamine, diarröa, veri roojas, apaatia ja neerukahjustused.
English: People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Estonian: Inimesed, kes on mittesteroidsete põletikuvastaste ravimite (NSAID) suhtes ülitundlikud, peaksid kokkupuudet veterinaarravimiga vältima.
English: Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Estonian: Mitte kasutada koertel, kel on sellised seedekulgla häired, nagu ärritus ja hemorraagia, kahjustunud maksa-, südame- või neerufunktsioon ja hemorraagilised häired.
English: Carton
Estonian: Corby
English: Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Estonian: Tüüpilised kõrvaltoimed, mida NSAIDe kasutamisel aeg-ajalt täheldatakse on isu kadu, oksendamine, diarröa, veri roojas, apaatia ja neerukahjustused.
English: Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Estonian: Mitte kasutada hobustel, kellel on seedetrakti häired, näiteks ärritus ja verejooks, maksa-, südame- või neerufunktsiooni kahjustus ja hemorraagilised häired.
English: Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment.
Estonian: Eelnev ravi põletikuvastaste ainetega võib põhjustada täiendavaid või raskemaid kõrvaltoimeid ja seetõttu tuleb enne ravi alustamist jätta vähemalt 24 tunnine ravivaba periood nende ravimitega.
English: Carton box 5 ml, 15 ml and 30 ml bottle
Estonian: 5 ml, 15 ml ja 30 ml pudel pappkarbis
English: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Estonian: Põletiku ja valu leevendamiseks nii ägedate kui ka krooniliste lihas-skeleti kahjustuste korral.
English: Shelf life after first opening the immediate packaging: 28 days.
Estonian: EXP: {kuu/aasta} Kõlblikkusaeg pärast vahetu pakendi esmast avamist: 28 päeva.
English: Sodium chloride Macrogol 300
Estonian: Meglumiin Glütsiin -Poloksameer 188 -Naatriumkloriid -Makrogool 300 -Vesinikkloriidhape Naatriumhüdroksiid -Süstevesi
English: Mode of Action
Estonian: Toimemehhanism
English: Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders.
Estonian: Põletiku ja valu leevendamiseks ägedate või krooniliste lihas-skeleti häirete korral.
English: Ref.: EMA/758850/2009 EMEA/H/C/391
Estonian: Viide: EMA/5542/2010 EMEA/H/C/391
English: This can result in serious loss of vision and even blindness.
Estonian: Selle tagajärjeks võib olla nägemise tugev halvenemine ja isegi pimedaksjäämine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lumigan to Allergan Pharmaceuticals Ireland on 8 March 2002.
Estonian: Euroopa Komisjon andis Lumigani müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Allergan Pharmaceuticals Ireland 8. märtsil 2002.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Lumigan's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Lumigani kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: This helps to reduce the pressure inside the eye and the risk of damage.
Estonian: See aitab alandada silma siserõhku ja vähendada kahjustuste riski.
English: Some of these patients carried on receiving the medicines for up to two or three years (379 and 183 patients, respectively).
Estonian: Osa neist (vastavalt 379 ja 183 patsienti) jätkas kuni kahe või kolme aasta jooksul nende ravimite kasutamist.
English: Lumigan bimatoprost EPAR summary for the public
Estonian: Lumigan bimatoprost Kokkuvõte üldsusele
English: Other information about Lumigan:
Estonian: Muu teave Lumigani kohta
English: Lumigan is used to reduce the pressure inside the eye.
Estonian: Lumigani kasutatakse silmasisese rõhu alandamiseks.
English: In all of the studies, the main measure of effectiveness was the reduction in eye pressure.
Estonian: Kõikides uuringutes oli efektiivsuse põhinäitajaks silmarõhu alanemine.
English: What is the risk associated with Lumigan?
Estonian: Mis riskid Lumiganiga kaasnevad?
English: However, the lower strength formulation was better tolerated and was less likely to cause hyperaemia (redness of the eye).
Estonian: Siiski taluti väiksema tugevusega ravimit paremini ja hüpereemia (silma liigveresus) tekke tõenäosus oli väiksem.
English: It is used in adults with long-term open angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) and in adults with ocular hypertension (when the pressure in the eye is higher than normal).
Estonian: Ravimit kasutatakse täiskasvanud patsientidel, kellel on pikaajaline avatud nurga glaukoom (haigus, mille korral silmasisene rõhk tõuseb, kui silma sisevedelik ei saa silmast ära voolata) või intraokulaarne hüpertensioon (kui silmasisene rõhk on normaalsest kõrgem).
English: Lumigan should not be used in people who may be hypersensitive (allergic) to bimatoprost or any of the other ingredients.
Estonian: Lumigani ei tohi kasutada patsiendid, kes võivad olla bimatoprosti või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The full EPAR for Lumigan is available here.
Estonian: Euroopa avaliku hindamisaruande täistekst Lumigani kohta on siin.
English: Lumigan contains benzalkonium chloride, which is known to discolour soft contact lenses.
Estonian: Lumigan sisaldab bensalkooniumkloriidi, mis teadaolevalt kahjustab pehmete kontaktläätsede värvi.
English: The recommended dose of Lumigan is one drop in the affected eye(s) once a day in the evening.
Estonian: Lumigani soovituslik annus on üks tilk haigesse silma üks kord ööpäevas õhtuti.
English: Lumigan acts in the same way and increases the flow of fluid out of the eye.
Estonian: Lumiganil on samasugune toime ja see suurendab vedeliku väljavoolu silmast.
English: In a patient with ocular hypertension or glaucoma, the value is generally higher than 21 mmHg.
Estonian: Intraokulaarse hüpertensiooni või glaukoomiga patsiendil on silmarõhk tavaliselt üle 21 mm Hg.
English: What is Lumigan?
Estonian: Mis on Lumigan?
English: It is available in two strengths, 0.1 and 0.3 mg per millilitre.
Estonian: Seda turustatakse kahes tugevuses: 0,1 mg/ml ja 0,3 mg/ml.
English: Why has Lumigan been approved?
Estonian: Miks Lumigan heaks kiideti?
English: Because Lumigan 0.1 mg/ml contains higher levels of benzalkonium chloride than Lumigan 0.3 mg/ml, Lumigan 0.1 mg/ml must not be used in people who have had a reaction to a product containing benzalkonium chloride in the past, and had to stop using the product containing it as a result.
Estonian: Et Lumigan 0,1 mg/ml sisaldab suuremas kontsentratsioonis bensalkooniumkloriidi kui Lumigan 0,3 mg/ml, ei tohi Lumigan 0,1 mg/ml kasutada patsientidel, kellel on esinenud bensalkooniumkloriidi sisaldavate ravimite suhtes vastureaktsioon ja nad on pidanud seetõttu ravimi kasutamise lõpetama.
English: The active substance in Lumigan, bimatoprost, is a prostaglandin analogue (a man-made copy of a natural substance, prostaglandin).
Estonian: Lumigani toimeaine bimatoprost on prostaglandiini analoog (loodusliku aine prostaglandiini sünteetiline variant).
English: Eye pressure is measured in ‘millimetres of mercury' (mmHg).
Estonian: Silmarõhku mõõdeti millimeetrites elavhõbedasammast (mm Hg).
English: The most common side effects with Lumigan (seen in more than 1 patient in 10) are conjunctival hyperaemia (increased blood supply to the eye, leading to redness).
Estonian: Kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on sidekesta hüpereemia (suurenenud verevool silma, mis põhjustab silma punetuse).
English: An additional 12-month study compared Lumigan 0.1 mg/ml with Lumigan 0.3 mg/ml, and with an intermediate strength of 0.125 mg/ml, in 561 patients.
Estonian: Täiendavas 12-kuulises uuringus võrreldi 561 patsiendil Lumigani toimet tugevuses 0,1 mg/ml, 0,3 mg/ml ja vahepealses tugevuses 0,125 mg/ml.
English: Lumigan has been studied in adults with glaucoma or ocular hypertension.
Estonian: Lumigani uuriti intraokulaarse hüpertensiooni ja glaukoomiga täiskasvanud patsientidel.
English: Lumigan can be used alone or with beta-blocker eye drops (other medicines used for these conditions).
Estonian: Lumigani võib kasutada ainsa ravimina või koos beetablokaator-silmatilkadega (samuti nende haigusseisundite ravimid).
English: Lumigan is a clear eye drop solution that contains the active substance bimatoprost.
Estonian: Lumigan on selge silmatilkade lahus, mis sisaldab toimeainena bimatoprosti.
English: Lumigan 0.1 mg/ml brought about slightly smaller decreases in IOP than Lumigan 0.3 mg/ml.
Estonian: Lumigan 0,1 mg/ml vähendas intraokulaarset rõhku pisut vähem kui Lumigan 0,3 mg/ml.
English: When the pressure inside the eye is raised, it causes damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Estonian: Silma siserõhu tõus kahjustab võrkkesta (silma tagaosas asuv valgustundlik membraan) ja silmanärvi, mis juhib silmast signaale ajju.
English: It has also been compared with latanoprost (another prostaglandin analogue used in glaucoma) in a six-month study involving 269 patients.
Estonian: Lumigani võrreldi ka latanoprostiga (samuti glaukoomi raviks kasutatav prostaglandiini analoog) kuuekuulises uuringus, milles osales 269 patsienti.
English: Lumigan's effect when added to beta-blocker treatment has also been compared with that of latanoprost in another study in 437 patients.
Estonian: Lumigani efektiivsust selle lisamisel ravile beetablokaatoriga võrreldi latanoprostiga veel ühes uuringus, milles osales 437 patsienti.
English: What benefit has Lumigan shown during the studies?
Estonian: Milles seisneb uuringute põhjal Lumigani kasulikkus?
English: In the eye, prostaglandin increases the drainage of the watery fluid (aqueous humour) out of the eyeball.
Estonian: Prostaglandiin suurendab vesivedeliku väljavoolu silmast.
English: Lumigan 0.3 mg/ml was also more effective than latanoprost, with patients using Lumigan achieving a reduction in eye pressure of 6.0 to 8.2 mmHg after six months of treatment compared with 4.9 to 7.2 mmHg with latanoprost.
Estonian: Lumigan 0,3 mg/ml oli efektiivsem ka latanoprostist: Lumigani kasutanud patsientidel saavutati pärast kuuekuulist ravi silmarõhu alanemine 6,0-8,2 mm Hg võrra, latanoprosti kasutamisel aga 4,9-7,2 mm Hg võrra.
English: How does Lumigan work?
Estonian: Kuidas Lumigan toimib?
English: The effect of adding Lumigan 0.3 mg/ml to existing treatment with a beta-blocker eye drop has been compared with that of adding placebo (a dummy eye drop) in one study involving 285 patients.
Estonian: Lumigan 0,3 mg/ml efektiivsust selle lisamisel olemasolevale ravile beetablokaator-silmatilkadega võrreldi platseebo (näiva ravitoimega silmatilgad) lisamisega ühes uuringus, milles osales 285 patsienti.
English: This effect was maintained after two or three years of treatment, with an average reduction in eye pressure of between 7.1 and 8.6 mmHg with Lumigan used once a day, compared with 4.6 to 6.4 mmHg with timolol.
Estonian: Ravimõju püsis ka pärast kahe- või kolmeaastast ravi, kusjuures Lumigani kasutamisel üks kord ööpäevas vähenes silmarõhk keskmiselt 7,1-8,6 mm Hg võrra, timolooli kasutamisel aga 4,66,4 mm Hg võrra.
English: What is Lumigan used for?
Estonian: Milleks Lumigani kasutatakse?
English: Lumigan 0.3 mg/ml used on its own has been compared with timolol (a beta-blocker used to treat glaucoma) in two 12-month studies involving a total of 1,198 patients.
Estonian: Lumigan 0,3 mg/ml kasutamist ainsa ravimina võrreldi timolooli (glaukoomi raviks kasutatav beetablokaator) kasutamisega kahes 12-kuulises uuringus, milles osales kokku 1198 patsienti.
English: Adding Lumigan 0.3 mg/ml to existing treatment with a beta-blocker was more effective than continuing to use the beta-blocker on its own.
Estonian: Lumigan 0,3 mg/ml lisamine olemasolevale beetablokaatoriga ravile oli efektiivsem kui ravi jätkamine ainult beetablokaatoriga.
English: How is Lumigan used?
Estonian: Kuidas Lumigani kasutatakse?
English: Lumigan was as effective as latanoprost when added to beta-blocker treatment, with reductions in eye pressure of 8.0 and 7.4 mmHg, respectively, after three months.
Estonian: Lumigan oli selle lisamisel ravile beetablokaatoriga vähemalt sama efektiivne kui latanoprost, kuna need alandasid silma siserõhku kolmekuulise ravi tulemusena vastavalt 8,0 ja 7,4 mm Hg võrra.
English: After three months, eye pressure was lowered by 7.4 mmHg in the group adding Lumigan, compared with 3.6 mmHg in the group adding placebo.
Estonian: Pärast kolmekuulist ravi oli rühmas, kus kasutati lisaks Lumigani, silmarõhk alanenud 7,4 mm Hg võrra, võrreldes 3,6 mm Hg-ga rühmas, kus kasutati lisaks platseebot.
English: How has Lumigan been studied?
Estonian: Kuidas Lumigani uuriti?
English: In addition, the following side effects are also seen in more than 1 patient in 10 using Lumigan 0.3 mg/ml: growth of eyelashes and ocular pruritus (itchy eye).
Estonian: Lisaks esinesid enam kui 1 patsiendil 10st Lumigan 0,3 mg/ml kasutamisel järgmised kõrvalnähud: ripsmete kasv ja okulaarne pruritus (silma kihelus) Lumigani kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Lumigan 0.3 mg/ml on its own was more effective than timolol at reducing eye pressure.
Estonian: Lumigan 0,3 mg/ml alandas selle kasutamisel ainsa ravimina silmarõhku efektiivsemalt kui timolool.
English: More information is available below.
Estonian: Lisateave on allpool.
English: The review of retinoid medicines was initiated on 8 July 2016 at the request of the United Kingdom, under Article 31 of Directive 2001/83/EC.
Estonian: Retinoide sisaldavate ravimite ravimiteabe läbivaatamine algas 8. juunil 2016 Ühendkuningriigi taotlusel vastavalt direktiivi 2001/83/EÜ artiklile 31.
English: Evidence from published literature and individual case reports is conflicting, and many published studies have a number of limitations.
Estonian: Avaldatud kirjanduse ja üksikteadete andmed on vastuolulised ning paljudel avaldatud uuringutel on piiranguid.
English: Updated measures for pregnancy prevention during retinoid use
Estonian: Ajakohastatud meetmed raseduse vältimiseks retinoidide kasutamise ajal